Herpes Labialis Drugs Market
Global Herpes Labialis Drugs Market Size, Share, and Trends Analysis Report, by Type (Acyclovir, Valacyclovir, Penciclovir, Famciclovir, and Docosanol), by Route of Administration (Oral, Topical, and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast Period (2022-2028) Update Available - Forecast 2024-2030
The global herpes labialis drugs market is anticipated to grow at a CAGR of 4.0% during the forecast period. Herpes labialis is a viral infection caused by the herpes simplex virus 1 (HSV-1). Herpes simplex virus type 1 (HSV-1) is a cause of recurrent vesiculoulcerative lesions of the oral or genital mucosa. It can also cause infection in the eye, skin, central nervous system, and/or visceral organs. Antiviral agents available for HSV infection include acyclovir, valacyclovir, and famciclovir. The growing prevalence of herpes labialis among children and adults across the globe is the factor that is driving the market growth. According to WHO, an estimated 3.7 billion people under age 50 (67%) have HSV-1 infection, and an estimated 491 million people aged 15–49 (13%) have HSV-2 infection globally. With increasing prevalence, it is expected that the demand for herpes labialis drugs will increase significantly.
Besides, the rising government programs for sexually transmitted disease awareness are expected to propel market growth. As HSV-2 is mainly transmitted during sex through contact with genital or anal surfaces, skin, sores, or fluids of someone infected with the virus. However, the high cost of treatment and strict government rules and regulations related to drug approval is expected to impact the growth of the market.
Segmental Outlook
The global herpes labialis drugs market is segmented based on type, route of administration, and distribution channel. Based on type, the market is sub-segmented into acyclovir, valacyclovir, penciclovir, famciclovir, and docosanol. Among these, the valacyclovir segment emerged as the fastest growing in the global herpes labialis drugs market. The drug is considered as finest for the treatment of herpes virus infections including herpes simplex viruses type 1 (HSV-1), type 2 (HSV-2), herpes labialis (cold sores), and herpes zoster(shingles), and herpes simplex(genital herpes). It helps in reducing the episode duration and time to healing. The increasing prevalence of herpes virus infections can lead to high demand for the drug, which in turn boosts market growth. As of 2016, 13.2% of the global population aged 15–49 was existing with HSV-2 infection and 66.6% with HSV-1. This high prevalence of the disease and the fact that resistance to current therapies is on the rise makes it imperative to develop and discover new methods of HSV prevention and management. Apart from these, acyclovir is likely to show the fastest growth during the forecast period. As acyclovir has the greatest in vitro activity against HSV-1 and HSV-2. However, famciclovir and valacyclovir have greater oral bioavailability than acyclovir and are dosed less frequently.
Based on the route of administration, the market is sub-categorized into oral, topical, and parenteral. Similarly, based on distribution channels, it is further divided into hospital pharmacies, retail pharmacies, and online pharmacies.
Regional Outlook
Geographically, the global herpes labialis drugs market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). The market in the Asia-Pacific is projected to expand at the fastest CAGR owing to the increasing government spending, and growing incidences of the herpes labialis in the region that are increasing the demand for herpes labialis drugs. Apart from these, the ongoing clinical trial in major economies of the region such as China, Singapore, and Malaysia are another significant factor that is likely to boost the market.
Global Herpes Labialis Drugs Market Growth By Region, 2022-2028
North America Region is Projected to Hold Considerable Share in Herpes Labialis Drugs Market
Geographically, the North American region held the highest share in the market in 2021. The region is expected to dominate by accounting for the largest share during the forecast period. The surge in the demand for drugs for herpes labialis, the existence of a well-developed pharmaceutical infrastructure for R&D activities, and the presence of major players in this region are the major factors driving the market growth. The US is expected to dominate the North American labialis drugs market due to the rapid surge in patient population and increasing research and development activities to develop highly specific herpes labialis drugs. The rising disposable income due to which people are investing more in healthcare acts as an opportunity for the growth of the market.
Market Players Outlook
The major market players in the global herpes labialis drugs market include Abbott Laboratories, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Dr. Reddy’s Laboratories., GlaxoSmithKline Plc, Mylan N.V., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., among others. The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. Apart from these, the ongoing trial for herpes simplex virus type vaccine development by these players can positively expand the global market size and give them new growth prospects to generate more revenue. For instance, in March 2021, GlaxoSmithKline (GSK) launched a limited phase 1 clinical trial for a herpes simplex virus type 2 (HSV-2) candidate known as the HSV vaccine (GSK4108771A).
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global herpes labialis drugs market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Herpes Labialis Drugs Market by Type
5.1.1. Acyclovir
5.1.2. Valacyclovir
5.1.3. Penciclovir
5.1.4. Famciclovir
5.1.5. Docosanol
5.2. Global Herpes Labialis Drugs Market by Route of Administration
5.2.1. Oral
5.2.2. Topical
5.2.3. Parenteral
5.3. Global Herpes Labialis Drugs Market by Distribution Channel
5.3.1. Hospital Pharmacies
5.3.2. Retail Pharmacies
5.3.3. Online Pharmacies
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
6.4.1. Latin America
6.4.2. Middle East & Africa
7. Company Profiles
7.1. Abbott Laboratories
7.2. Alembic Pharmaceuticals, Ltd.
7.3. Apotex, Inc.
7.4. Aurobindo Pharma Ltd.
7.5. Bausch Health Companies, Inc.
7.6. Blistex, Inc.
7.7. Cipla, Ltd.
7.8. GlaxoSmithKline Plc
7.9. Hikma Pharmaceuticals PLC
7.10. Jubilant Cadista
7.11. LGM Pharma
7.12. Mylan N.V.
7.13. Novartis AG
7.14. Pfizer, Inc.
7.15. Sun Pharmaceutical Industries, Ltd.
7.16. Taj Pharmaceuticals, Ltd.
7.17. Teva Pharmaceutical Industries, Ltd.
7.18. Torrent Pharmaceuticals, Ltd.
7.19. Valeant Pharmaceuticals International Inc. (Bausch Health)
7.20. Zydus Cadila, Ltd.
1. GLOBAL HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL ACYCLOVIR HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL VALACYCLOVIR HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL PENCICLOVIR HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL FAMCICLOVIR HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL DOCOSANOL HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
8. GLOBAL ORAL HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL TOPICAL HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL PARENTERAL HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
12. GLOBAL HERPES LABIALIS DRUGS IN HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL HERPES LABIALIS DRUGS IN RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL HERPES LABIALIS DRUGS IN ONLINE PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16. NORTH AMERICAN HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. NORTH AMERICAN HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
18. NORTH AMERICAN HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
19. NORTH AMERICAN HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
20. EUROPEAN HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. EUROPEAN HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
22. EUROPEAN HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
23. EUROPEAN HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
24. ASIA-PACIFIC HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
25. ASIA-PACIFIC HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
26. ASIA-PACIFIC HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
27. ASIA-PACIFIC HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
28. REST OF THE WORLD HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
29. REST OF THE WORLD HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
30. REST OF THE WORLD HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
31. REST OF THE WORLD HERPES LABIALIS DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1. GLOBAL HERPES LABIALIS DRUGS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
2. GLOBAL HERPES LABIALIS DRUGS MARKET SHARE BY ROUTE OF ADMINISTRATION, 2021 VS 2028 (%)
3. GLOBAL HERPES LABIALIS DRUGS MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
4. GLOBAL HERPES LABIALIS DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
5. GLOBAL ACYCLOVIR HERPES LABIALIS DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
6. GLOBAL VALACYCLOVIR HERPES LABIALIS DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
7. GLOBAL PENCICLOVIR HERPES LABIALIS DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
8. GLOBAL FAMCICLOVIR HERPES LABIALIS DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
9. GLOBAL DOCOSANOL HERPES LABIALIS DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
10. GLOBAL ORAL HERPES LABIALIS DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
11. GLOBAL TOPICAL HERPES LABIALIS DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
12. GLOBAL PARENTERAL HERPES LABIALIS DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
13. GLOBAL HERPES LABIALIS DRUGS IN HOSPITAL PHARMACIES MARKET SHARE BY REGION, 2021 VS 2028 (%)
14. GLOBAL HERPES LABIALIS DRUGS IN RETAIL PHARMACIES MARKET SHARE BY REGION, 2021 VS 2028 (%)
15. GLOBAL HERPES LABIALIS DRUGS IN ONLINE PHARMACIES MARKET SHARE BY REGION, 2021 VS 2028 (%)
16. US HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
17. CANADA HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
18. UK HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19. FRANCE HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. GERMANY HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. ITALY HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. SPAIN HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF EUROPE HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. INDIA HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. CHINA HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
26. JAPAN HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
27. SOUTH KOREA HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF ASIA-PACIFIC HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
29. REST OF THE WORLD HERPES LABIALIS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
